BioSpace News Archive

Model Medicines, today announced preclinical results demonstrating once daily, oral dosing of MDL-001 significantly reduces the viral load of SARS-CoV-2 (the virus that causes COVID-19) in the lungs of an established mouse-adapted animal model of SARS-CoV-2 infection (two-way ANOVA, P < 0.01).

MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics™), today announced a groundbreaking partnership with the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN) to participate in a multicenter randomized clinical trial substudy of its PocketECG® technology.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today a decision from InEK in Germany that Revita has been granted Status 1 designation under its NUB funding process.

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol ® Cyclo™, at WORLD Symposium 2022.

Intrommune Therapeutics, Inc. today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy.

Neuvivo today announced the expansion of its Advisory Board, adding James Kovach, MD, JD as a new member.

Schrödinger announced that management will provide a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference.

Expression Therapeutics, Inc. announced that Chief Executive Officer, Dr. Mohan Rao, was selected to present at the BIO CEO & Investor Conference in New York City from February 14-16 and participate in one-on-one investor meetings.

Blackrock Neurotech, the leader in brain-computer interface technology, has signed an exclusive license for Columbia University’s neural decoder MINT.

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva ® .